#USA #Fremont, California #Ultima Genomics #Gene by Gene #UG 100 platform

Enhancing Global Access to Genetic Sequencing

In a significant move to democratize genomic technology, Ultima Genomics, Inc., known for its innovative UG 100™ next-generation sequencing (NGS) platform, has announced a partnership with Gene by Gene. This collaboration aims to broaden access to high-quality, cost-effective DNA sequencing services worldwide.

A New Era of DNA Sequencing

The partnership between Ultima Genomics and Gene by Gene marks a milestone in the realm of genetic testing. Gene by Gene will join a network of Certified Service Providers utilizing Ultima's advanced sequencing capabilities. This network includes notable names like Broad Clinical Labs, New York Genome Center, and the University of Minnesota Genomics Center, all of which contribute to the increasingly crucial field of genomic medicine.

This collaboration allows Gene by Gene to enhance its service offerings, which cover a wide spectrum of genomic applications, including clinical assessments, research initiatives, direct-to-consumer testing, and forensic analysis. The UG 100’s scalability presents an unparalleled opportunity for Gene by Gene to provide industry-leading DNA analysis services, adhering to the highest standards of precision and affordability.

Innovations in Genetic Testing

Jay Therrien, the Chief Commercial Officer of Ultima Genomics, emphasized the significance of this partnership, stating that it not only expands access to the UG 100 platform but also supports a range of genome sequencing applications. His remarks underline the platform's ability to facilitate groundbreaking research and innovation in genetics at an unprecedented scale.

On the other side, Josh Wittner, President of Gene by Gene, noted that the partnership is consistent with the company's mission. He highlighted the importance of maintaining quality while making advanced genetic testing more accessible. By utilizing the transformative power of the UG 100 technology, Gene by Gene can deliver high-volume sequencing outputs without compromising the integrity of the results.

The UG 100 Sequencing Platform Advantage

The UG 100 sequencing platform, along with the newly launched UG 100 Solaris™ technology, is set to redefine the landscape of genomics. Solaris boasts a 50% increase in sequencing output compared to previous methodologies, allowing for up to 12 billion reads per wafer. This advancement not only reduces sequencing costs but also simplifies the workflows for users, creating more efficient processes in genomic data handling.

As humanity stands at the brink of a biological revolution, the integration of Ultima’s cutting-edge sequencing technologies with Gene by Gene’s expertise signals a new dawn for genomic research. The collaboration promises to democratize genomic information, catering to the complex needs of various research sectors and clinical practices.

Looking Forward

Both companies view this alliance as an important step towards the future of genomic sciences. With vast implications for healthcare, research, and personalized medicine, it aims to propel genomic studies to new heights, empowering scientists and medical professionals alike. As the demand for genomic data grows, the partnership between Ultima Genomics and Gene by Gene exemplifies a shared commitment to innovation and accessibility in genetic testing.

In conclusion, as the world becomes increasingly reliant on genetic insights for health and research advancements, collaborations like this are essential. They not only enhance the capabilities within the genome sequencing landscape but also offer more inclusive access to the transformative power of genetic knowledge.